January 14, 2005

Skinvisible Announces New Board of Directors Member

LAS VEGAS, Jan 14, 2005 /PRNewswire-FirstCall via COMTEX/ --

Skinvisible, Inc. (OTC Bulletin Board: SKVI) (Website: www.skinvisible.com) is pleased to announce the election of Mr. Greg McCartney to the Board of Directors at the Annual General Meeting held on January 10, 2005. McCartney is presently President, CEO and Chairman of American Stock Exchange listed Genesis Bioventures (Amex: GBI). Mr. McCartney has over 20 years experience serving as officer and director of both private and public companies in various manufacturing and technology industries. Prior to founding Genesis Bioventures in 1997, Mr. McCartney was owner and director of a private consulting firm specializing in financing and venture capital. "Mr. McCartney's experience in the Biotech & Healthcare industry in the area of licensing will be a major asset as we continue forward in licensing our Invisicare(R) delivery technology," said Terry Howlett.

Headquartered in Las Vegas, Nevada, Skinvisible, Inc. is focused on the development of innovative topical polymer-based delivery systems and related technologies incorporating its patented formula/process for combining hydrophilic and hydrophobic polymers into stable water emulsions. Skinvisible's primary marketing and sales objectives are to license its technologies and/or sell its delivery systems to provide enhanced product performance for established brand manufacturers and providers of prescription, over-the-counter, cosmetic, and skincare products. In addition Skinvisible formulates and manufactures products for private label customers.

This press release contains "forward looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports that will be on file with the US Securities and Exchange Commission (including but not limited to the report on Form 10-QSB for the quarter ending September 30, 2004).

SOURCE Skinvisible, Inc.

T. Howlett of Skinvisible, Inc., +1-702-433-7154, or fax, +1-702-433-7192, terry@skinvisible.com; or Tommi Hanley of Thompson Lloyd Communications, +1-250-860-9959, tommi.tlc@shaw.ca, for Skinvisible, Inc.

Press Release Index

New Press Release Alerts:

If you are interested in receiving corporate and new product development news from Skinvisible, simply enter your email address below.